Data Sheet (Cat.No.T11296)

TargetMol

Flosulide

Chemical Properties



CAS No. : 80937-31-1

Formula: C16H13F2NO4S

Molecular Weight: 353.34

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Flosulide is an effective selective COX-2 inhibitor for the treatment of inflammatory diseases.
Targets(IC50)	COX
In vitro	Flosulide entirely inhibits the mitotic activity of OSC-2 cells while having no impact on the mitotic activity of OSC-1 cells. Additionally, Flosulide demonstrates a concentration-dependent effect on the OSC-2 cell line by fully suppressing PGE2 production across a range of 1 nM to 100 μM; however, it does not affect prostaglandin (PG) synthesis in OSC-1 cells.
In vivo	In normovolemic rats, flosulide enhances renal plasma flow (RPF) and glomerular filtration rate (GFR), while in hypovolemic rats, it reduces these measures at dosages between 5-25 mg/kg. At a dosage of 5 mg/kg, flosulide lowers 6-keto-PGF1alpha, and at 25 mg/kg or following 10 mg/kg of indomethacin, it leads to a decrease in both 6-keto-PGF1alpha and TXB2[1]. Furthermore, flosulide at 0.75 mg/day notably decreases proteinuria compared to aspirin treatment and results in significantly higher plasma protein and albumin levels than those observed in aspirin-treated rats[3].

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.8301 mL	14.1507 mL	28.3014 mL
5 mM	0.566 mL	2.8301 mL	5.6603 mL
10 mM	0.283 mL	1.4151 mL	2.8301 mL
50 mM	0.0566 mL	0.283 mL	0.566 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Turull A, et al. Acute effects of the anti-inflammatory cyclooxygenase-2 selective inhibitor, flosulide, on renal plasma flow and glomerular filtration rate in rats. Inflammation. 2001 Apr;25(2):119-28.
Zimmermann KC, et al. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. 1999 Jan 1;59 (1):198-204.
Heise G, et al. Different actions of the cyclooxygenase 2 selective inhibitor flosulide in rats with passive Heymann nephritis. Nephron. 1998 Oct;80(2):220-6.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481